Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X:
“Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial British Journal of Haematology | Wiley Online Library
PCNSL First-Line Trial – Compact Summary
- Design: Prospective, multicentre trial (2019–2024)
- Patients: 48 newly diagnosed PCNSL
- Regimens:
• Group A: RLZT + MTX (≤65 yrs, normal renal fxn)
• Group B: RLZT alone (>65 yrs or renal dysfunction) - Strategy: 6 courses → ASCT if eligible; maintenance zanubrutinib if not
- Endpoints: ORR & CR (primary); PR, PFS, OS (secondary)
- Results: Good efficacy & safety
- Key Takeaway: Promising frontline option for elderly/unfit patients unable to tolerate intensive chemo.”
Title: Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial
Authors: Jia Song, Huijuan Jiang, Kai Ding, Hui Liu, Yihao Wang, Shan Gao, Yue Ren, Zhaoyun Liu, Jie Zhuo, Bing Li, Guokai Wang, Zongjiu Jiao, Da Gao, Rong Fu
Raed Full Article.
More posts featuring Mostafa Faisal on OncoDaily.